Prospective multicentre systematic guideline-based management of patients referred to the Syncope Units of general hospitals
…, R Maggi, E Vitale, A Morrione, GM Francese… - Europace, 2010 - academic.oup.com
Aims Although an organizational model for syncope management facilities was proposed in
the 2004 guidelines of the European Society of Cardiology (ESC), its implementation in …
the 2004 guidelines of the European Society of Cardiology (ESC), its implementation in …
Update on management of cardiovascular diseases in women
…, F Giallauria, A Leone, GM Francese… - Journal of clinical …, 2022 - mdpi.com
Cardiovascular diseases (CVD) have a lower prevalence in women than men; although, a
higher mortality rate and a poorer prognosis are more common in women. However, there is a …
higher mortality rate and a poorer prognosis are more common in women. However, there is a …
ANMCO Position paper: Management of hypercholesterolemia in patients with acute coronary syndrome
…, M Corda, A De Nardo, GM Francese… - Giornale Italiano di …, 2023 - europepmc.org
Patients suffering from acute coronary syndromes (ACS) present a high risk of recurrence
and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-…
and new adverse cardiovascular events after hospital discharge. Elevated plasma LDL-…
Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper
…, M Cipriani, S Domenicucci, GM Francese… - Journal of …, 2021 - journals.lww.com
The central role of high low-density lipoprotein cholesterol levels in atherosclerotic cardiovascular
disease has led to research focused on lipid-lowering agents for cardiovascular risk …
disease has led to research focused on lipid-lowering agents for cardiovascular risk …
ANMCO position paper: guidance for the management of suspected or confirmed COVID-19 patients requiring urgent electrophysiological procedures
…, F Colivicchi, GM Francese… - Giornale italiano di …, 2020 - pubmed.ncbi.nlm.nih.gov
… 3 , Giuseppina Maura Francese …
[HTML][HTML] Remote monitoring: Doomed to let down or an attractive promise?
…, A Madeo, D Fiscella, D Benedetto, GM Francese… - IJC Heart & …, 2019 - Elsevier
Device interrogation and management are time consuming, representing a relevant burden
for pacing centers. In several situations, patients' management requires additional follow up …
for pacing centers. In several situations, patients' management requires additional follow up …
[引言][C] Position paper ANMCO: Organizzazione della Rete per il trattamento dei pazienti con sindrome coronarica acuta durante emergenza pandemica COVID-19
…, S Domenicucci, GM Francese… - Giornale Italiano di …, 2020 - giornaledicardiologia.it
La pandemia COVID-19 è diventata un’emergenza sanitaria planetaria 1, 2. Il numero dei
contagi da SARS-CoV-2 in Italia è in rapido aumento e ciò che emerge dalle stime attuali è …
contagi da SARS-CoV-2 in Italia è in rapido aumento e ciò che emerge dalle stime attuali è …
Rate-responsive pacing regulated by cardiac haemodynamics
…, L Bontempi, G Mascioli, G Maura Francese… - EP …, 2005 - academic.oup.com
Aims Trans-valvular impedance (TVI) recording has been proposed for the assessment of
cardiac haemodynamics, assuming an inverse relationship between TVI and ventricular …
cardiac haemodynamics, assuming an inverse relationship between TVI and ventricular …
Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper
…, M Cipriani, S Domenicucci, GM Francese… - Journal of …, 2021 - journals.lww.com
Bloodstream cholesterol is a central contributor to atherosclerotic cardiovascular diseases.
For several decades, low-density lipoprotein cholesterol (LDL-C) has been the main …
For several decades, low-density lipoprotein cholesterol (LDL-C) has been the main …
ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation
…, M Corda, A De Nardo, GM Francese… - European Heart …, 2022 - academic.oup.com
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first
developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been …
developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been …